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Quantifying the contribution of changes in
healthcare expenditures and smoking to
the reversal of the trend in life expectancy
in the Netherlands
Frederik Peters1*, Wilma J. Nusselder1, Nadine Reibling2, Christian Wegner-Siegmundt3 and Johan P. Mackenbach1
Abstract
Background: Since 2001 the Netherlands has shown a sharp upturn in life expectancy (LE) after a longer period of
slower improvement. This study assessed whether changes in healthcare expenditure (HCE) explain this reversal in
trends in LE. As an alternative explanation, the impact of changes in smoking behavior was also evaluated.
Methods: To quantify the contribution of changes in HCE to changes in LE, we estimated a health-production
function using a dynamic panel regression approach with data on 19 OECD countries (1980–2009), accounting for
temporal and spatial correlation. Smoking-attributable mortality was estimated using the indirect Peto-Lopez
method.
Results: As compared to 1990–1999, during 2000–2009 LE in the Netherlands increased by 1.8 years in females and
by 1.5 years in males. Whereas changes in the impact of smoking between the two periods made almost no
contribution to the acceleration of the increase in LE, changes in the trend of HCE added 0.9 years to the LE
increase between 2000 and 2009. The exceptional reversal in the trend of LE and HCE was not found among the
other OECD countries.
Conclusion: This study suggests that changes in Dutch HCE, and not in smoking, made an important contribution
to the reversal of the trend in LE; these findings support the view that investments in healthcare are increasingly
important for further progress in life expectancy.
Keywords: Healthcare systems, Life expectancy, Smoking
Background
Since the 19th century life expectancy at birth has in-
creased dramatically in Western high-income coun-
tries [1]. During the second part of the 20th century
the rate of increase in most of these countries was
very similar, with no disruptions or signs of slowing
down [2, 3]. This remarkable finding led to the belief
that progress in survival is a universal feature largely
independent of country-specific aspects, such as the
set-up of the health system or differences in health-
specific behavior [2]. However, this hypothesis was
challenged by some particularly successful economies
witnessing longer periods with a slower increase, or
even stagnation, in life expectancy [4–6].
An example for such a country is presented by the
Netherlands, where mortality declined more slowly than
in other countries during the 1980s and 1990s, particu-
larly for women [7]. However, in the year 2002 a sudden
and strong increase in life expectancy started and has
continued until today [8]. One hypothesis for this rever-
sal in trend is that additional investments in the health
sector led to improvements in survival, particularly at
older ages [8]. On the other hand, an exceptionally high
impact of damage caused by smoking has frequently
been mentioned as a competing explanation, particularly
relevant during the stagnation period of Dutch life
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expectancy improvements [4, 9]. Despite considerable
research, no convincing evidence is available on the fac-
tors behind the stagnation period and the subsequent
period of resumption of the improvement in Dutch life
expectancy [10].
Therefore, this study is the first to quantify the impact
of healthcare expenditure on the change from a slower
increase to a rapid improvement in Dutch life expect-
ancy, while also assessing the contribution of smoking as
an alternative explanation. Additionally, we evaluated
whether the internationally deviating trends in Dutch life
expectancy corresponded to internationally deviating
trends in healthcare expenditures or smoking.
For this purpose, we compared the results from the
Netherlands with a group of 18 comparable countries
of the Organization for Economic Co-operation and
Development (OECD) based on data covering life expect-
ancy, lung cancer mortality, healthcare expenditures and
gross domestic product for the years 1980–2009. To esti-
mate the impact that changes in healthcare expenditures
had on life expectancy we used a panel data analysis ac-
counting for unobserved factors, cross-country vari-
ation, and dynamic effects. The impact of smoking was
estimated by the indirect Peto-Lopez method.
Methods
Data collection
Countries included in the analysis were all members of
the OECD since (at least) 1980, because the annual
provision of country-specific data is legally linked to this
membership status. Excluded were Luxembourg because
it provides data on healthcare expenditures from 1999 on-
wards only, and the USA due to its fundamentally differ-
ent healthcare system [11]. This leaves the following 19
countries for analysis: Australia, Austria, Belgium, Canada,
Denmark, Finland, France, Iceland, Ireland, Italy, Japan,
the Netherlands, Norway, New Zealand, Portugal, Spain,
Sweden, Switzerland and the United Kingdom.
Information on mortality rates for the ages 0 to 100
in 5-year age groups were obtained from the Human
Mortality Database [12]. Sex-specific lung cancer death
rates in 5-year age groups for ages 35 to 89 years were
taken from the WHO mortality database to obtain
smoking-attributable fractions [13]. To model the influ-
ence of healthcare expenditures on life expectancy at
birth, we collected data on healthcare expenditures and
gross-domestic product (GDP) for the years 1980–2009
from the 2014 OECD Health Data collection [14].
Statistical analysis
The analysis quantified the contribution of changes in
smoking and healthcare expenditures to changes of life
expectancy at birth, between 1990 and 2009, using two
different techniques.
The impact of smoking on mortality was estimated
using the validated indirect Peto-Lopez method, which
utilizes lung cancer death rates as an indicator for the cu-
mulative damage of smoking to all other causes of death
on the basis of relative risks obtained from a large cohort
study [15]. This resulted in country-specific annual
smoking-attributable fractions in 5-year age groups from
age 35 to 85 years and an open-ended category 85+. These
fractions were used to remove smoking-related mortality
from the observed mortality rates, that were also tabulated
in annual 5-year age groups to compute smoking-free life
expectancy applying life table methods. The smoking-
attributable fraction at age 85+ years was applied only to
mortality between age 85–90 years because, at older ages,
the impact of smoking is very small and cause-of-death
statistics are less trustworthy [15]. For a few calendar years
for which lung cancer deaths were missing, we interpo-
lated smoking-attributable fractions using local polyno-
mial regression fitting.
Because competing strategies to estimate the impact
of healthcare expenditures on life expectancy have been
proposed in the literature [16–18], we performed a sep-
arate analysis beforehand comparing different model
approaches (presented in detail in the Additional file 1).
In brief, we estimated a health-production function re-
lating monetary inputs in healthcare to gains in life ex-
pectancy building on recent developments in the
analysis of relationships in panel data. Specifically, we
modelled a dynamic response of life expectancy to
changes in healthcare spending and allowed for hetero-
geneity in this relation between countries [18]. Thereby,
the model tests whether there is an immediate and/or
delayed effect of changes in healthcare spending on
changes in life expectancy by merely assuming that the
size of the delayed effect declines geometrically over
time. Moreover, we included spatially correlated com-
mon factors in the production function accounting for
the fact that developments in the countries do not
occur independently of each other [17]. Our theoretic-
ally preferred model was compared to alternative speci-
fications on the basis of model fit and panel residual
diagnostics. In our main analysis, we multiplied the pa-
rameters of this preferred model with the changes in
country-specific healthcare expenditures to quantify
their impact on life expectancy between 1980 and 2009.
Finally, we compared the gain in life expectancy in
1990–1999 and in 2000–2009 with the gains attributed
to changes in smoking and with gains due to increases
in healthcare expenditures for the Netherlands and the
average of the other 18 countries. Thereby, life expect-
ancy at birth was computed using life table analysis [19].
Although the trend break in Dutch life expectancy oc-
curred around 2002 and not in 2000, for the sake of
more robust results we decided to compare the most
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recent decade to the preceding one so that the analysis
covered 10 full calendar years respectively. We com-
puted 95 % confidence intervals (CIs) around the esti-
mates of the impact of healthcare expenditures since
their contribution is more uncertain than the contribu-
tion of smoking. This was performed by means of
simulation (10000 runs) using the variance-covariance
matrix of the panel regression results. We used STATA
13 and GNU R 3.1.1 for the calculations.
Results
Descriptive trends
Comparing the Netherlands to the average of the other
18 OECD countries shows that Dutch life expectancy in-
creases at a slower rate up until about 2002 and faster
thereafter, which was more pronounced for females
(Fig. 1).
Trends in the age-standardized lung cancer death rate,
which served as input for the estimation of smoking-
associated mortality, reveal large gender differences
(Fig. 2). The exceptionally high lung cancer death rate in
Dutch males in 1990 decreased rapidly over time, while
Dutch females exhibited increasing rates during the en-
tire study period.
The pattern of trends in healthcare expenditures partly
resembled the pattern of trends in life expectancy (Fig. 2):
expressed as a proportion of the GDP, healthcare expen-
ditures in the Netherlands stagnated up until 2001 and
rose thereafter, whereas in the other countries there was
a continuous increase over time.
Effect of changes in healthcare expenditures on life
expectancy
A dynamic relationship between healthcare expenditures
and life expectancy was confirmed in our sample of 19
countries in 1980–2009 (see Additional file 1): a 10 %
increase in healthcare expenditures translates into an in-
crease of life expectancy of 0.36 % on the long term
(95 % CI: 0.26-0.58). Given a level of life expectancy of
80 years this would amount to an increase of 0.29 years
or 3.5 months.
Impact of changes in healthcare expenditures and
smoking on changes in life expectancy
The contribution of changes in healthcare expenditures
to changes in life expectancy is shown in Fig. 3. While
Dutch females and males gained about one year of life
between 1990 and 2009, this gain was more modest for
the other OECD countries on average. The impact of
healthcare spending in the Netherlands remained stable
until about 2000 followed by a rapid increase thereafter.
On average the other countries show a continuous linear
increase.
The impact of changes in smoking on changes in life
expectancy between 1990 and 2009 occurred in a linear
manner for both the Netherlands and the mean of the
other countries (Fig. 3). Dutch women suffered above-
average losses of years of life due to more damage from
smoking while Dutch men gained above-average years of
life due to less damage from smoking.
Table 1 summarizes the impact of changes in smoking
and healthcare expenditures. Compared to the period
1990–1999, in the period 2000–2009 the change in
Dutch life expectancy accelerated by 1.8 years in females
and by 1.5 years in males. Changes in healthcare expen-
ditures contributed 0.9 years to this trend, whereas
changes in smoking had practically no impact. Taking
into account the uncertainty around the estimates, a
conservative estimate would ascribe at least 20 % of the
acceleration in the improvement of Dutch life expect-
ancy (0.29 years in females and 0.27 years in males) to
larger changes in healthcare spending.
Fig. 1 Trends in female and male life expectancy at birth in the Netherlands and in 18 other OECD countries between 1990 and 2009
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Fig. 2 Change in age-standardized lung cancer death rate between age 35 and 89 per 100,000 persons in females and males (upper panel) and
healthcare expenditures measured in percentage of gross-domestic product (GDP) (lower panel) in the Netherlands (solid line) and the mean of
18 other OECD countries (dashed line) between 1990 and 2009. Note: Lung-cancer death rates were age-standardized based on the 2013 European
Standard Population for illustrative purposes only
Fig. 3 Estimated impact of changes in smoking and healthcare expenditures on life expectancy at birth in females (left panel) and males
(right panel) in the Netherlands and the mean of 18 other OECD countries between 1990 and 2009
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Table 1 Decennial change in life expectancy (LE) at birth and contribution of smoking and healthcare expenditures (HCE) in the Netherlands and the mean of 18 other OECD
countries, 1990–1999 and 2000–2009
Period Observed change in LE Difference between
1990–1999 and
2000–2009
Change in LE
due to changes
in smoking
Difference between
1990–1999 and
2000–2009
Change in
LE due to
changes in HCE
95 % CI Difference between
1990–1999 and 2000–2009
95 % CI
Females The Netherlands
1990–99 0.3 −0.6 0.0 (0.01 to 0.05)
2000–09 2.1 1.8 −0.4 0.2 1.0 (0.30 to 1.62) 0.9 (0.29 to 1.57)
Mean of the other countries
1990–99 1.7 −0.1 0.3 (0.09 to 0.52)
2000–09 1.9 0.2 −0.1 0.0 0.5 (0.14 to 0.77) 0.2 (0.05 to 0.25)
Males The Netherlands
1990–99 1.5 0.7 0.0 (0.01 to 0.04)
2000-09 3.0 1.5 0.5 −0.2 0.9 (0.27 to 1.49) 0.9 (0.27 to 1.45)
Mean of the other countries
1990–99 2.2 0.4 0.3 (0.09 to 0.47)
2000–09 2.5 0.3 0.3 −0.1 0.4 (0.13 to 0.70) 0.1 (0.00 to 0.20)
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On average there were no large differences in the
change of life expectancy or in the change of the impact
of smoking and healthcare expenditures in the group of
the other countries. Interestingly, the slightly larger
change in life expectancy during 2000–2009 as com-
pared to 1990–1999 can almost fully be attributed to a
slightly larger change of healthcare expenditures.
Sensitivity analysis
To assess the robustness of our results, we used an alter-
native indicator for healthcare expenditures (per capita
healthcare expenditures expressed in US$) and estimated
smoking-attributable fractions with a different regression-
based approach, as suggested by Preston and colleagues
[20]. This did not substantially change the main findings
of our analysis (see Additional file 1).
Also, we portioned the data into two different segments
directly covering the years before (1994–2001) and after
(2002–2009) the trend reversal in life expectancy oc-
curred. Although this alternative analysis covered fewer
years of observation (16 instead of 20 years in total), the
estimates were virtually the same (see Additional file 1).
Discussion
This study is the first quantitative assessment of the con-
tribution of healthcare expenditures to the recent trend
reversal of Dutch life expectancy, also accounting for the
contribution of smoking. Our results suggest that
changes in healthcare expenditures contributed largely
to the trend reversal, with hardly any contribution being
made by changes in smoking.
Moreover, the exceptionally large impact of changes in
healthcare expenditures on life expectancy were indeed
a unique feature of the Netherlands and not present to
the same extent in our comparison group of 18 OECD
countries.
Evaluation of data
Since we included only high-income countries with well-
established systems of national statistics that were mem-
bers of the OECD for at least as long as the study
period, we are confident about the comparability and
quality of the data in general. Missing information that
often casts doubt on international comparison was not
an issue, since our sample had almost complete informa-
tion on the study variables [18]. Data on all-cause mor-
tality and population exposure, as well as healthcare
expenditures and GDP, were obtained from harmonized
databases. Nevertheless, some caveats apply for certain
aspects of the data. The implementation of the OECD
system of health accounts framework underlying the
data on healthcare expenditures varied among countries
and over time limiting the comparability. Thereby, dif-
ferences in the definition of costs for long-term care
were identified as most important issue affecting the
share of HCE to GDP up to 1 percentage points [21]. To
cope with such inconsistencies, we used different statis-
tical models and sample compositions, suggesting that
our results are generally robust against these inconsist-
encies (see Additional file 1). Information on lung cancer
counts is (as is the case with all cause-of-death specific
data) subject to uncertainty due to variations in national
coding practices and changes in coding behavior over
time [22]. However, these issues are of minor relevance
for lung cancer data because detection is relatively clear
and coding schemes have been established for a long
time without drastic changes [23].
Evaluation of methods
The most important part of our study is the quantifica-
tion of the effect of changes in healthcare expenditures
on changes in life expectancy. Although there is a longer
tradition of assessing this relationship in empirical re-
search, there is no consensus on the appropriate strategy
to estimate it [16]. We believe this is largely due to the
absence of appropriate tools to analyze panel data, that
became available only a few years ago [18, 24]. A main
insight of this new literature is that the relation between
healthcare expenditures and life expectancy can be esti-
mated more reliably for a group of countries than for an
individual country alone [25]. However, this comes at
the cost of providing only “insights regarding the central
tendency of the panel” so that we had to apply the same
parameter for every country in the main part of our
analysis to compute the contribution of healthcare ex-
penditures on life expectancy [26]. Nevertheless, this
assumption seems plausible for the countries in our
sample, as they share similar political and economic
structures, and all provide almost full public coverage
of basic healthcare services [27]. If there were sub-
stantial differences in the efficiency of the production
of health between the Netherlands and the other 18
countries, this would be likely within the relatively
large confidence intervals around our main results
representing the large uncertainty about the effect of
changes in healthcare expenditures.
In our analysis, we assumed that variations in healthcare
spending causally explain variations in life expectancy
ruling out the opposite direction, i.e., that improve-
ments in life expectancy cause additional costs in the
health sector. A study explicitly testing the influences
of such reverse causality found that improvements in
most health outcomes did not led to higher healthcare
costs [28]. Furthermore, it is reported that with postpon-
ing death also costs are postponed, deeming increases in
life expectancy to be less relevant for growing healthcare
expenditures [29]. An exception is spending on long-term
care that is to a large extent driven by population ageing
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[30]. Evaluating the influence of long-term care on health-
care expenditures on our estimates is hardly possible since
this aspect of the OECD data is particularly imprecisely
measured, as explained above.
Regarding the effect of smoking, we applied a well-
established tool that has proven reliable and informative
in numerous applications [31, 32]. Although the indirect
modeling of the damage from smoking on other causes-
of-death partly relies on a set of assumptions, different
approaches with different assumption arrived at very
similar estimates [20, 33]. Furthermore, the estimated
smoking-attributable fractions plausibly describe the
variation of the timing in the epidemiological transitions
between countries and sexes [32, 34].
An important assumption of our study is that the
contribution of healthcare expenditures and smoking
on trends in life expectancy could be quantified inde-
pendently of each other. This might be a simplistic view,
given that a well-funded healthcare system certainly miti-
gates the consequences of smoking, particularly for
smoking-induced cardiovascular diseases for which effect-
ive treatments exist. However, due to the lack of evidence
on that topic, it is difficult to speculate on the impact of
our assumption on the study results.
Comparison with other studies
The results of this study underpin the hypothesis that
changes in healthcare expenditures were the main driver
of the trend reversal of life expectancy in the
Netherlands [8]. While previous analyses only demon-
strated the presence of a common trend break for these
two variables at around 2002, our study shows that: 1)
changes in healthcare spending were generally positively
associated with changes in life expectancy within high-
income countries, 2) the size of the impact of healthcare
could plausibly explain the acceleration of the Dutch life
expectancy increase, 3) the exceptionally large changes
in healthcare spending and the trend reversal in life ex-
pectancy at around 2002 was a particular feature of the
Netherlands, and 4) that the major alternative explan-
ation for the trend reversal, i.e., changes in smoking,
could be ruled out. These four aspects explaining the
Dutch trend reversal counter arguments stating: “that
there is no observable relationship with changes health-
care funding whatsoever” [10].
The importance of the contribution of healthcare ex-
penditures to the trend reversal in Dutch life expectancy
is in line with case studies of other countries with rapid
trend reversals in life expectancy. The natural experi-
ment of the separation and subsequent unification of
Germany demonstrated that improvements of the
healthcare infrastructure could affect life expectancy im-
mediately and with a large impact [35]. In Denmark, a
huge investment program to reduce cardiovascular
mortality was held partially responsible for the upturn in
Danish life expectancy after a longer period of stagna-
tion [36]. The same was noted for the case of Ireland,
where particularly cardiovascular mortality suddenly de-
clined after access to primary care and pharmaceuticals
was facilitated in 2001 [37]. The results of our main ana-
lysis confirm the findings for Denmark and Ireland that
increases in healthcare expenditures in these countries
contributed to the accelerations of the increase in life
expectancy (see Additional file 1).
Nevertheless, the example of Japan shows that a large
increase in life expectancy can be achieved without a
large increase in healthcare spending, while the ex-
ample of the USA shows that substantial investments
in healthcare spending do not necessarily lead to large
improvements in life expectancy [38, 39]. This high-
lights the relevance of contextual factors, such as a uni-
versal coverage of healthcare services or more general
cultural aspects. Clearly, investments in healthcare sys-
tems have a larger impact on life expectancy in coun-
tries where costly but also effective medical treatments
were held back.
Our results attributed a considerable part of the increase
in Dutch life expectancy to changes in Dutch healthcare
expenditures, i.e., about 47 % for Dutch women and about
30 % for Dutch men in 2000–2009. Studies that combined
knowledge on the effect of new medical treatments with
cause-specific mortality data and disease prevalence, esti-
mated that innovations in healthcare have contributed to
at least 50 % of the gains in life expectancy during recent
decades, which is in line with our estimates [40].
Explanations of findings
A major way in which variations in Dutch healthcare ex-
penditures could have affected mortality, is the budgeting
of hospital care. During the early 1980s, at the time the
improvements in Dutch life expectancy started to slow
down, policymakers introduced fixed hospital budgets
resulting in a considerable reduction in the admission of
new patients, of employed personnel and even in the clos-
ure of some hospitals [41, 42]. To cope with the budgeting
of their resources hospitals invested less in new medical
technologies and limited the volume of treatment for their
patients [42]. Together with the legalization of euthanasia
in 1985 and an increasing incidence of end-of-life de-
cisions (e.g., the withdrawal of artificial nutrition), this
reflected a general attitude towards a less aggressive
treatment of older and terminally-ill patients [7].
Consequently, the dramatic improvements in survival
due to innovations in the treatment of cardiovascular
diseases observed in many Western countries particu-
larly at older ages, where probably not fully realized
in the Netherlands where mortality rates even in-
creased for some age groups [3, 4].
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At the end of the 1990s, complaints about excessive
waiting times for elective surgeries piled up, so that pol-
icymakers abolished the fixed hospital budgets at the
end of 2000 and replaced them with activity-based fund-
ing [43]. As a result hospital admissions, treatments, and
pharmaceutical prescriptions increased rapidly, particu-
larly among the elderly [8]. Thereby, effective life-saving
treatments, e.g., lipid- and blood pressure lowering
drugs, were applied more often and prescribed to older
patients than before the reform [8, 44]. This more active
medical treatment potentially explains the reversal in
mortality trends from diabetes, stroke, pneumonia and
symptoms and ill-defined conditions [8]. That the
change in healthcare expenditures was not merely driven
by higher prices of care was also confirmed by earlier
analyses that ascribed about two-thirds of the increase
to an extension of the volume of care [45].
The precise causal mechanisms how more spending
translated into better survival in the Netherlands need
to be understood in more detail. Recent studies revealed
that particularly the survival of persons with more severe
chronic conditions improved during the trend reversal
of Dutch life expectancy, which indirectly confirms a
possible impact of improved healthcare [46, 47]. How-
ever, so far the decline in mortality could not be linked
to healthcare utilization at the individual level [46].
Although the impact of smoking did not explain the
trend reversal in Dutch mortality it did affect trends in
life expectancy. During the study period, the lower gains
in life expectancy for Dutch women, as compared to
Dutch men, were to a large extent caused by smoking;
this is in line with the general theory of the smoking
transition through which women progress with a delay
of several decades as compared to men [48]. It has been
reported that, after the exclusion of smoking-related
causes of death, the stagnation in mortality decline oc-
curred at the same time for men and women [7]. Our
study results show that also the resumption of Dutch
mortality decline after 2001 was similar for men and
women, when the differential impact of smoking was
accounted for. This concordance of sex-specific life ex-
pectancy trends before and after the Dutch trend rever-
sal calls for a more general explanation that affected all
Dutch inhabitants in the same way; we believe we have
identified this in the form of financing of healthcare. No
other plausible alternative explanation, that could have
affected men and women in the same way, is available.
Conclusions
The findings of this study highlight the growing im-
portance of policy decisions regarding the allocation
of healthcare resources. The case of the Netherlands
demonstrates that changes in healthcare expenditures
considerably affect trends in life expectancy.
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